Loading...

Member Profile

Established in 1998, with robust growth of revenue, profit and marketing channel, TCM Biotech International Corp. is a biotech company specializing in innovative research and development of new drug and as the second company ratified by Taiwan’s Ministry of Economic Affairs to be a “Biotechnology New Drug Company” for the remarkable R&D capability and achievement. With TQF certification “Medical Fungi Fermentation Factory” was established in Tainan Hsin-Ying Industrial Park mainly responsible for the providing the required principal active ingredient for the health supplements development.

This company focuses on the development of new drug and diagnosis for the prevention and treatment of liver disease as its product development spindle: PTX-9908 combined with TACE for liver cancer, Liver cancer early detection test “CatCHimera “circulating ctDNA biomarker for HCC and comprehensive patent-layout. In addition to the establishment of Taiwan’s professional marketing team, it’s also strategically in alliance with China partners to build up the marketing channel network, gradually expand to international market and then well-applying of revenue profit into the development of specialty products and new drug. Furthermore, it’s showed that the R&D capacity of this company has been recognized by government for the subsidization support during pre-clinical and clinical trial stage of new drug development.

Looking ahead, TCM Biotech will turn into an international biotech company professional in the R&D, manufacturing and marketing of new drug in prevention and treatment of liver disease. And well utilize the advantage of channel, product feature, completion strength to bring in maximum revenue and profit as goal.


Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2013 TCM Biotech signed TCM-700C formal technology licensing agreement with China partner Shanghai Rui Jian.
   2014 TCM Biotech obtained the US patent “Pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease.”
   2014 TCM Biotech obtained the US patent “METHODS FOR MAKING AND COMPOSITIONS COMPRISING FERMENTATION PRODUCTS OF CORDYCEPS SINENSIS.”
   2014 TCM Biotech obtained the US patent “Pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease.”
   2015 The developing new drug “HBV Combination New Drug”(Program number: TCM-800-01-01)has obtained the approval from TFDA for the Phase II human clinical implementation.
   2017 Established GDP-compliant pharmaceutical warehouse. (GDP: Good Distribution Practice)
   2017 Patents for liver cancer early detection platform ” CatCHimera ” were granted in Taiwan, European, Japan, and Singapore.(2017~2018 )
   2019 The developing new drug “PTX-9908”has obtained the IND approval from US FDA/TW TFDA for the Phase I/II human clinical implementation.
   2019 The developing new drug “PTX-9908 ”for treatment of Hepatocellular carcinoma has obtained the Orphan-drug designation(ODD) from US FDA.
   2020 The New Indication New Drug”U101” has obtained the IND approval from TW TFDA for the Phase III human clinical implementation.
   2021 The following patents were granted in Taiwan. 1. New Indication New Drug U101 for“Pharmaceutical composition for prevention of recurrent urinary tract infection” 2. liver cancer early detection platform ” CatCHimera ” for Probe Combination for Detection of Cancer 3. new drug “PTX-9908 ”for “Therapeutic Combination and Method for Treating Cancer”